A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab monotherapy in subjects with moderate to severe atopic dermatitis who are candidates for systemic therapy - ECZTRA 1

EO Pharma A/S0 sites780 target enrollmentJune 28, 2017

Overview

No summary available.

Registry

who.int

Start Date

June 28, 2017

End Date

TBD

Last Updated

6 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

EO Pharma A/S

•Age 18 and above
•Diagnosis of AD as defined by the Hanifin and Rajka (1980\) criteria for AD.
•Diagnosis of AD for \=1 year.
•Subjects who have a recent history of inadequate response to treatment with topical medications or for whom topical treatments are otherwise medically inadvisable.
•AD involvement of \=10% body surface area at screening and baseline.
•An EASI score of \=12 at screening and 16 at baseline.
•An IGA score of \=3 at screening and at baseline.
•A Worst Daily Pruritus numeric rating scale (NRS) average score of \=4
•during the week prior to baseline.
•Stable dose of emollient twice daily for at least 14 days before randomisation.

•Active dermatologic conditions that may confound the diagnosis of AD.
•Use of tanning beds or phototherapy within 6 weeks prior to randomisation.
•Treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic corticosteroid within 4 weeks prior to randomisation.
•Treatment with TCS and/or TCI within 2 weeks prior to randomisation.
•Active skin infection within 1 week prior to randomisation.
•Clinically significant infection within 4 weeks prior to randomisation.
•A helminth parasitic infection within 6 months prior to the date informed consent is obtained.
•Tuberculosis requiring treatment within the 12 months prior to screening.
•Known primary immunodeficiency disorder.